Duke Comp Cancer Inst. Core Support Grant

最近重组的杜克综合癌症研究所（DCCI）负责作为中心， 所有杜克在癌症方面的活动，并有必要在未来监督所有杜克癌症手术。作为 作为最大的生物医学研究所之一的矩阵中心，DCCI一直在不断 通过利用杜克的基础研究， 具有显著临床肿瘤学研究卓越的优势，通过治疗5，581例新 癌症患者，每年招募1,000多名患者进行治疗性临床试验，并加强 国家肿瘤学研究资源的存在，如两个国家的数据和统计中心， 国家癌症研究所资助的合作团体。DCCI的成员总数为285名，其中成员拥有 自2004年以来，癌症研究的重点日益突出，NCI的资助金额也有所增加。总 为方案成员提供的资金为331 617 013美元，其中269 525 804美元来自同行审查来源。一 癌症焦点由NCI，美国癌症协会或美国癌症协会的77，785，582美元或23.5%的资金说明。 国防部从2004年到2008年，项目成员在同行评审中发表了6,941篇论文。 PubMed中引用的期刊。在这些出版物中，10%是方案内合作的结果， 19%是由于项目间的合作。在此竞争性续约申请中，我们请求支持 我们在11个研究项目中的成员资格，由17个共享资源支持。DCCI成员 重大的科学进步，包括：创新的基因组测试的发展，以预测哪些癌症 患者将对特定的化疗产生反应，并对癌症中的关键信号通路有基本的了解。 和发育生物学。DCCI监督杜克所有与癌症相关的慈善事业，这些基金 已被用于支持新成员的招聘，创新的试点项目，支持多学科 研究，以及新的实验室和行政空间。本申请持续支持 国防协调委员会阐明了推动国防协调委员会充分利用 在杜克和其他地方，生物医学研究取得了巨大进展，以改善和延长癌症的生命 癌症患者和有癌症风险的患者，并将这些患者提供给社会。

The recently reorganized Duke Comprehensive Cancer Institute (DCCI) is charged to serve as the center of all Duke activities in cancer, with an imperative to oversee all of the Duke cancer operations in the future. As a matrix center in one of the largest biomedical research institutes, the DCCI has been continuously supported by the National Cancer Institute (NCI) for over 36 years, by leveraging Duke's basic research strengths with significant clinical oncology research excellence which is enabled by treating 5,581 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. Total membership in the DCCI is 285 members, with members having an increasingly prominent focus in cancer research and increased amount of NCI funding since 2004. Total funding for program members is $331,617,013, of which $269,525,804 is from peer-reviewed sources. A cancer focus is illustrated by $77,785,582 or 23.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 6,941 papers in peer-reviewed journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and 19% due to inter-programmatic collaborations. In this competitive renewal application, we request support our membership in 11 Research Programs supported by 17 Shared Resources. DCCI members made significant scientific advances including: the development of innovative genomic tests to predict which cancer patients would respond to specific chemotherapy, and basic insight into critical signaling pathways in cancer and developmental biology. The DCCI oversees all cancer related philanthropy at Duke, and these funds have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary research, and new laboratory and administrative space. This application for ongoing support of the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.